ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)
Anumana, Inc. · K253801
FDA-authorized Predetermined Change Control Plan
- Company
- Anumana, Inc.
- 510(k)/De Novo #
- K253801
- Decision date
- 2026-04-07
- Panel
- Cardiovascular
- Pathway
- 510(k)
- Category
- AI/SaMD
- PCCP type
- I/O expansion
- Monitoring commitment
- Not stated
What this PCCP covers. Permits input/output expansion to compatible devices
Other PCCPs from Anumana, Inc.
Other Cardiovascular PCCPs
- K253152BP1000 Ultra-Compact Fingertip Blood Pressure Monitor (BP1000)Biozen, LLC2026-05-06AI hardwareRetraining
- K260212EnSite X EP SystemABBOTT MEDICAL2026-04-20AI hardwareHardware
- K252945Novasight Hybrid SystemConavi Medical, Inc.2026-04-17AI hardwareRetraining
- K252360ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)Anumana, Inc.2026-03-28AI/SaMDRetraining
- K252972CARTO 3 EP Navigation System V8.4Biosense Webster, Inc.2026-02-20AI hardwareRetraining
- K252589Corvair MonzaAliveCor, Inc.2026-01-09AI/SaMDRetraining
Want the monitoring teardown?
We read the PCCP for ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040), then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.
Book a callSource: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.
This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.